Abiopharma

🔍 Pocock Jane (Executive)

Company: COPART INC (CPRT)

Report Date: 2026-08-16

Detailed Transactions and Holdings:

• Acquired 25,308 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: false | shares_owned_after: 25,308.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 500,000 shares of Stock Options at $31.61 per share (Derivative)
  Date: 2026-08-16 | Code: A | Expires: 2036-08-13 | equity_swap_involved: false | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Copart, Inc. common stock.
• F2: Twenty percent of the Restricted Stock Units (RSUs) vest on the first anniversary of the grant date (August 16, 2027), and the balance vests cumulatively at a rate of 1/20 each three month quarter thereafter, such that 100% of the RSUs will vest on the fifth anniversary of the grant date.
• F3: 100% of the stock options are subject to time -based vesting, with 20% of the stock options vesting on the first anniversary of the grant date, and the balance vesting at a rate of 1/60 per month thereafter, such that 100% of the stock options will vest and become exerciseable on the fifth anniversary of the grant date. In addition to the time-based vesting, 279,000 of the stock options are subject to an additional performance-based vesting condition and will not be exerciseable unless and until the trading price of the Copart, Inc. Common Stock in trading on the Nasdaq Global Select Market is an amount greater than or equal to $39.51 (125% of the per share exercise price) both (1) at the moment of any exercise, and (2) at the closing price for each of the twenty consecutive trading days preceding the date of any exercise.